Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 28, 2017 - Issue 6
Submit an article Journal homepage
1,685
Views
35
CrossRef citations to date
0
Altmetric
Psoriasis

The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients

Michael AbroukUniversity of California, Irvine School of Medicine, Irvine, CA, USA; Correspondence[email protected]
,
M. NakamuraUCSF Department of Dermatology, San Francisco, CA, USA;
,
T. H. ZhuUSC School of Medicine, Los Angeles, CA, USA;
,
B. FarahnikUniversity of Vermont School of Medicine, Burlington, VT, USA
,
J. KooUCSF Department of Dermatology, San Francisco, CA, USA;
&
T. BhutaniUCSF Department of Dermatology, San Francisco, CA, USA;
Pages 488-491 | Received 25 Nov 2016, Accepted 22 Dec 2016, Published online: 18 Jan 2017

References

  • Gelfand JM, Dommasch ED, Shin DB, et al. The risk of stroke in patients with psoriasis. J Invest Dermatol. 2009;129:2411–8.
  • Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296:1735–41.
  • Alsufyani MA, Golant AK, Lebwohl M. Psoriasis and the metabolic syndrome. Dermatol Ther. 2010;23:137–43.
  • Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and hypertension: a systematic review and meta-analysis of observational studies. J Hypertens. 2013;31:433–42.
  • Lee MSS, Lin RYY, Lai MSS. Increased risk of diabetes mellitus in relation to the severity of psoriasis, concomitant medication, and comorbidity: a nationwide population-based cohort study. J Am Acad Dermatol. 2014;70:691–8.
  • Rapp SR, Exum ML, Reboussin DM, et al. The physical, psychological and social impact of psoriasis. J Health Psychol. 1997;2:525–37.
  • Perrott SB, Murray AH, Lowe J, Mathieson CM. The psychosocial impact of psoriasis: physical severity, quality of life, and stigmatization. Physiol Behav. 2000;70:567–71.
  • Lundberg L, Johannesson M, Silverdahl M, et al. Health-related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity. Acta Derm Venereol. 2000;80:430–4.
  • Augustin M, Krüger K, Radtke MA, et al. Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology (Basel). 2008;216:366–72.
  • Pearce DJ, Singh S, Balkrishnan R, et al. The negative impact of psoriasis on the workplace. J Dermatol Treat. 2006;17:24–8.
  • Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210–6.
  • Grossi E, Groth N, Mosconi P, et al. Development and validation of the short version of the Psychological General Well-Being Index (PGWB-S). Health Qual Life Outcomes. 2006;4:88.
  • Basra MK, Hussain S. Application of the dermatology life quality index in clinical trials of biologics for psoriasis. Chin J Integr Med. 2012;18:179–85.
  • Revicki DA, Willian MK, Menter A, et al. Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis. J Dermatol Treat. 2007;18:341–50.
  • Herrier RN. Advances in the treatment of moderate-to-severe plaque psoriasis. Am J Health Syst Pharm. 2011;68:795–806.
  • Carlin CS, Feldman SR, Krueger JG, et al. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol. 2004;50:859–66.
  • Strober BE, van de Kerkhof P, Bachelez H. Is PASI 90 becoming the new PASI 75? (26AD). Bruce Jancin Frontline Medical News. Available from http://www.mdedge.com/rheumatologynews/article/78483/psoriasis/pasi-90-becoming-new-pasi-75. Accessed October 24, 2013.
  • Langley R, Elewski BE, Lebwohl M, et al. Secukinumab in Plaque psoriasis-results of two phase 3 trials. N Engl J Med. 2014;371:326–38.
  • Papp K, et al. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment. J Am Acad Dermatol. 2014;71:1183–90.e3.
  • Wenger NK. National Heart Lung and Blood Institute. Assessment of Quality of Life in Clinical Trials of Cardiovascular Therapies. Washington (DC): Le Jacq Publishing, 1984.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.